Atlas Special Opportunities

Acheter-Louer.fr is a company that focuses on internet-based real estate services, providing a platform for buying, selling, renting, and leasing properties. It specializes in publishing small professional real estate advertisements, catering to both individuals and real estate professionals. Through its online services, Acheter-Louer.fr aims to facilitate property transactions by connecting buyers, sellers, and renters in a streamlined manner. The company's offerings contribute to the evolving landscape of real estate, leveraging digital solutions to meet the needs of its users.

Circio Holding ASA is a clinical-stage biotechnology company dedicated to developing and commercializing immuno-oncology therapies aimed at treating resistant solid tumors. The company's lead product candidate, ONCOS-102, is a genetically modified oncolytic adenovirus designed to infect cancer cells and stimulate the immune system's response against tumors. In addition to ONCOS-102, Circio is advancing other candidates in its pipeline, including circVec and Mutant KRAS, which focus on targeted immunotherapy treatments for cancer patients. The company's innovative approach leverages cutting-edge genetic engineering to enhance the efficacy of cancer treatments, with a commitment to addressing the challenges posed by treatment-resistant cancers.

Oxurion is a clinical-stage biopharmaceutical company based in Belgium, focused on developing advanced ophthalmic therapies aimed at preserving vision in patients suffering from retinal vascular disorders. Its primary target conditions include diabetic macular edema, wet age-related macular degeneration, and retinal vein occlusion, which are significant causes of vision loss worldwide. The company is dedicated to creating innovative treatments that enhance the standard of care for these debilitating eye diseases.

Oxurion is a clinical-stage biopharmaceutical company based in Belgium, focused on developing advanced ophthalmic therapies aimed at preserving vision in patients suffering from retinal vascular disorders. Its primary target conditions include diabetic macular edema, wet age-related macular degeneration, and retinal vein occlusion, which are significant causes of vision loss worldwide. The company is dedicated to creating innovative treatments that enhance the standard of care for these debilitating eye diseases.

Oxurion is a clinical-stage biopharmaceutical company based in Belgium, focused on developing advanced ophthalmic therapies aimed at preserving vision in patients suffering from retinal vascular disorders. Its primary target conditions include diabetic macular edema, wet age-related macular degeneration, and retinal vein occlusion, which are significant causes of vision loss worldwide. The company is dedicated to creating innovative treatments that enhance the standard of care for these debilitating eye diseases.

Oxurion is a clinical-stage biopharmaceutical company based in Belgium, focused on developing advanced ophthalmic therapies aimed at preserving vision in patients suffering from retinal vascular disorders. Its primary target conditions include diabetic macular edema, wet age-related macular degeneration, and retinal vein occlusion, which are significant causes of vision loss worldwide. The company is dedicated to creating innovative treatments that enhance the standard of care for these debilitating eye diseases.

TME Pharma is a clinical-stage biopharmaceutical company focused on enhancing cancer treatment by targeting the tumor microenvironment. The company develops biostable aptamers and mirror image nucleic acids, with its leading drug candidates, NOX-A12 and NOX-E36, derived from a novel class of therapeutics known as Spiegelmers. These compounds are designed to improve the effectiveness of existing cancer therapies by offering specific advantages over traditional drug classes. TME Pharma maintains a strategic alliance with Pfizer, Inc., underscoring its commitment to advancing innovative treatment options in oncology. The company is headquartered in Berlin, Germany.

Circio Holding ASA is a clinical-stage biotechnology company dedicated to developing and commercializing immuno-oncology therapies aimed at treating resistant solid tumors. The company's lead product candidate, ONCOS-102, is a genetically modified oncolytic adenovirus designed to infect cancer cells and stimulate the immune system's response against tumors. In addition to ONCOS-102, Circio is advancing other candidates in its pipeline, including circVec and Mutant KRAS, which focus on targeted immunotherapy treatments for cancer patients. The company's innovative approach leverages cutting-edge genetic engineering to enhance the efficacy of cancer treatments, with a commitment to addressing the challenges posed by treatment-resistant cancers.

Drone Volt SA is a manufacturer and distributor of professional civilian drones, headquartered in Villepinte, France. Established in 2011, the company operates in multiple countries, including Belgium, the Netherlands, Canada, Denmark, the United States, Switzerland, and Indonesia. Drone Volt provides a range of commercial drones designed for various applications such as inspection, surveillance, thermography, and search and rescue missions, targeting sectors like energy, construction, security, and agriculture. In addition to its own drone products, the company also distributes DJI drones and accessories for civil and commercial use. Drone Volt offers a comprehensive suite of services, including engineering consulting, aerial data acquisition, professional drone training, maintenance, and legal support. The company serves a diverse clientele, including government agencies and industrial groups, while also exporting its products globally.

TME Pharma is a clinical-stage biopharmaceutical company focused on enhancing cancer treatment by targeting the tumor microenvironment. The company develops biostable aptamers and mirror image nucleic acids, with its leading drug candidates, NOX-A12 and NOX-E36, derived from a novel class of therapeutics known as Spiegelmers. These compounds are designed to improve the effectiveness of existing cancer therapies by offering specific advantages over traditional drug classes. TME Pharma maintains a strategic alliance with Pfizer, Inc., underscoring its commitment to advancing innovative treatment options in oncology. The company is headquartered in Berlin, Germany.

TME Pharma is a clinical-stage biopharmaceutical company focused on enhancing cancer treatment by targeting the tumor microenvironment. The company develops biostable aptamers and mirror image nucleic acids, with its leading drug candidates, NOX-A12 and NOX-E36, derived from a novel class of therapeutics known as Spiegelmers. These compounds are designed to improve the effectiveness of existing cancer therapies by offering specific advantages over traditional drug classes. TME Pharma maintains a strategic alliance with Pfizer, Inc., underscoring its commitment to advancing innovative treatment options in oncology. The company is headquartered in Berlin, Germany.

Circio Holding ASA is a clinical-stage biotechnology company dedicated to developing and commercializing immuno-oncology therapies aimed at treating resistant solid tumors. The company's lead product candidate, ONCOS-102, is a genetically modified oncolytic adenovirus designed to infect cancer cells and stimulate the immune system's response against tumors. In addition to ONCOS-102, Circio is advancing other candidates in its pipeline, including circVec and Mutant KRAS, which focus on targeted immunotherapy treatments for cancer patients. The company's innovative approach leverages cutting-edge genetic engineering to enhance the efficacy of cancer treatments, with a commitment to addressing the challenges posed by treatment-resistant cancers.